ProQR Therapeutics N.V. (PRQR)

NL — Healthcare Sector
Peers: ANNX  ARWR  DAWN  TERN  ALNY  WVE  BPMC  APLS  ASMB  SPRO  ACHL  TIL  NLTX  CTMX  NXTC  NUVB 

Automate Your Wheel Strategy on PRQR

With Tiblio's Option Bot, you can configure your own wheel strategy including PRQR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol PRQR
  • Rev/Share 0.1805
  • Book/Share 0.7496
  • PB 1.9476
  • Debt/Equity 0.2135
  • CurrentRatio 4.0953
  • ROIC -0.2673

 

  • MktCap 153607823.61
  • FreeCF/Share -0.3606
  • PFCF -4.0456
  • PE -5.0931
  • Debt/Assets 0.1111
  • DivYield 0
  • ROE -0.5358

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 3
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Resumed PRQR Cantor Fitzgerald -- Overweight -- $8 April 29, 2025
Initiation PRQR Evercore ISI -- Outperform -- $5 April 29, 2025
Upgrade PRQR Citigroup Neutral Buy -- $4 March 10, 2025
Initiation PRQR Oppenheimer -- Outperform -- $15 Jan. 10, 2025

News

ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences
PRQR
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral

LEIDEN, Netherlands & CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomerâ„¢ RNA editing technology platform, today announced that it will present at two upcoming scientific conferences: the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting, taking place May 13-17, 2025, in New Orleans, Louisiana and the TIDES USA 2025: Oligonucleotide and Peptide Therapeutics Conference, being held May 19-22, 2025, in San Diego, California.

Read More
image for news ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences
ProQR Announces First Quarter 2025 Operating and Financial Results
PRQR
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral

LEIDEN, Netherlands & CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer RNA editing technology platform, today reported its financial and operating results for the first quarter ended March 31, 2025, and provided a business update.

Read More
image for news ProQR Announces First Quarter 2025 Operating and Financial Results
ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025
PRQR
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral

LEIDEN, Netherlands & CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

Read More
image for news ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025
ProQR (PRQR) Reports Q4 Loss, Lags Revenue Estimates
PRQR
Published: March 13, 2025 by: Zacks Investment Research
Sentiment: Negative

ProQR (PRQR) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.08 per share a year ago.

Read More
image for news ProQR (PRQR) Reports Q4 Loss, Lags Revenue Estimates

About ProQR Therapeutics N.V. (PRQR)

  • IPO Date 2014-09-18
  • Website https://www.proqr.com
  • Industry Biotechnology
  • CEO Mr. Daniel Anton de Boer
  • Employees 166

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.